Skip to main content

This job has expired

You will need to login before you can apply for a job.

Scientist, DNA Encoded Chemistry, Library Discovery

Employer
Nurix Therapeutics
Location
San Francisco, CA, United States
Start date
Aug 3, 2021

View more

Discipline
Science/R&D, Biotechnology, Chemistry
Required Education
Bachelors Degree
Position Type
Full time
Hotbed
Biotech Bay

Job Details

Company

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix's extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix's drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels.

Nurix's wholly owned pipeline comprises targeted protein degraders of Bruton's tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California.

About the Position

We are seeking a talented and highly motivated chemist with a strong background in synthetic organic chemistry and familiarity with the application of DNA encoded chemistry to join our Library Discovery team. You will join a group with two objectives: 1) Design and synthesize DNA encoded libraries and 2) Utilize these libraries to identify novel chemical matter with the potential to modulate the activity of UPS targets.

You will have demonstrated experience in synthetic organic chemistry and analytical methods. Experience with DNA encoded library synthesis, parallel reaction chemistry, split/pool methods, aqueous chemistry and linker chemistry related to the synthesis of drug conjugates are all valued skills. Understanding of the physicochemical properties that drive drug discovery are desired. As a member of a dynamic multi-disciplinary project team, this person will collaborate with a broad group of scientists within Nurix as well as with external collaborators.

Qualifications
  • Ph.D. in synthetic organic chemistry with 0-5 years industrial chemistry experience (years of relevant experience will impact level of hire).
  • Expert in synthetic organic chemistry methods and analytical tools, in particular LCMS
  • High level of creativity and productivity with strong synthetic problem-solving skills.
  • Solid track record of scientific accomplishment demonstrated by publications, patents, or presentations
  • Excellent communication skills and able to present the rationale, key data, issues and accomplishments of the chemistry efforts to other members of the department.
  • Familiarity with principles of combinatorial chemistry and DNA encoded library technology
  • Interest in optimizing chemical reactions for use in DNA encoded library synthesis.
  • Familiarity with working with large data sets and the tools necessary to effectively organize, visualize and distill data to facilitate rapid decision making.

Fit with Nurix Culture and Values
  • Strong team orientation; highly collaborative
  • Solutions and results-oriented focus
  • Hands-on approach; resourceful and open to diverse points of view

Company

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels.

Nurix’s wholly owned pipeline comprises targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California.

Company info
Website
Phone
415-660-5320
Location
1700 Owens Street
Suite 205
San Francisco
California
94158
US

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert